We are live on ! Find out more
ORMP icon

Oramed Pharmaceuticals
ORMP

61 hedge funds and large institutions have $9.3M invested in Oramed Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 9 increasing their positions, 21 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

288% more call options, than puts

Call options by funds: $314K | Put options by funds: $81K

1.51% more ownership

Funds ownership: 9.21% → 10.72% (+1.5%)

21% less funds holding

Funds holding: 77 → 61 (-16)

48% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 29

57% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 21

78% less capital invested

Capital invested by funds: $43.2M → $9.3M (-$33.9M)

Holders
61
Holders Change
-16
Holders Change %
-20.78%
% of All Funds
0.97%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
9
Reduced
21
Closed
29
Calls
$314K
Puts
$81K
Net Calls
+$233K
Net Calls Change
-$1.39M

Top Buyers

Rank Fund Capital Flow
1
BCM
BML Capital Management
Indiana
+$4.31M
2
Two Sigma Investments
Two Sigma Investments
New York
+$1.61M
3
Two Sigma Advisers
Two Sigma Advisers
New York
+$613K
4
SIGI
Susquehanna International Group (Ireland)
Ireland
+$361K
5
XT
XTX Topco
Cayman Islands
+$300K

Top Sellers

Rank Fund Capital Flow
1
LC
Lindbrook Capital
California
-$4.61M
2
Millennium Management
Millennium Management
New York
-$1.03M
3
JP Morgan Chase
JP Morgan Chase
New York
-$732K
4
Russell Investments Group
Russell Investments Group
United Kingdom
-$680K
5
Man Group
Man Group
United Kingdom
-$665K
Name Holding Trade Value Shares
Change 		Change in
Stake
Cambridge Investment Research Advisors
26
Cambridge Investment Research Advisors
Iowa
$40K +$19.7K +6,188 +51%
Geode Capital Management
27
Geode Capital Management
Massachusetts
$39.5K – – –
Osaic Holdings
28
Osaic Holdings
Arizona
$39.3K -$14K -4,403 -20%
SSA
29
Schonfeld Strategic Advisors
New York
$37.9K +$55.3K +17,400 New
DC
30
Diametric Capital
Massachusetts
$31.2K +$45.5K +14,314 New
Susquehanna International Group
31
Susquehanna International Group
Pennsylvania
$30.9K -$545K -171,417 -92%
Invesco
32
Invesco
Georgia
$29.2K +$42.5K +13,375 New
TSS
33
Two Sigma Securities
New York
$28.3K +$41.2K +12,962 New
AS
34
Altshuler Shaham
Israel
$28K – – –
Renaissance Technologies
35
Renaissance Technologies
New York
$26K +$37.8K +11,900 New
Northern Trust
36
Northern Trust
Illinois
$25.2K -$835 -263 -2%
Marshall Wace
37
Marshall Wace
United Kingdom
$23K -$85.3K -26,846 -72%
Royal Bank of Canada
38
Royal Bank of Canada
Ontario, Canada
$22K -$6.35K -2,000 -17%
CAM
39
Close Asset Management
United Kingdom
$19K +$18.1K +5,700 +178%
IA
40
IFP Advisors
Florida
$13.9K – – –
BCM
41
Bourgeon Capital Management
Connecticut
$12.3K – – –
EWM
42
Endurance Wealth Management
Rhode Island
$12K -$3.18K -1,000 -15%
DAM
43
Draper Asset Management
New York
$11.6K -$14.8K -4,654 -47%
HNB
44
Huntington National Bank
Ohio
$11K – – –
Wells Fargo
45
Wells Fargo
California
$8.94K -$192K -60,582 -94%
ME
46
McIlrath & Eck
Washington
$6.54K – – –
Northwestern Mutual Wealth Management
47
Northwestern Mutual Wealth Management
Wisconsin
$3.43K – – –
Fidelity Investments
48
Fidelity Investments
Massachusetts
$3.05K -$115K -36,286 -96%
CHC
49
City Holding Co
West Virginia
$2.33K – – –
CFGS
50
Concourse Financial Group Securities
Alabama
$2.18K – – –
1
2
3 4

ORMP Hedge Fund Activity: Q1 2023 in Review

61 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q1 2023, worth a combined $9.3M — down 78% from $43.2M a quarter earlier.

Sellers outnumbered buyers: 29 funds closed out of ORMP and 15 opened new positions — a net loss of 14 holders — while 21 trimmed existing stakes and 9 added.

The largest buyer was BML Capital Management, opening a new position worth an estimated $4.31M. The largest seller was Lindbrook Capital, exiting entirely with an estimated $4.61M sold.

  • 61 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q1 2023, down from 77 in Q4 2022.
  • Funds reported $9.3M of Oramed Pharmaceuticals stock for Q1 2023, down 78% quarter-over-quarter.
  • 15 funds opened new Oramed Pharmaceuticals positions in Q1 2023 and 29 closed out, a net change of -14 holders.
  • The largest Oramed Pharmaceuticals buyer in Q1 2023 was BML Capital Management, an estimated $4.31M added.
  • The largest Oramed Pharmaceuticals seller in Q1 2023 was Lindbrook Capital, an estimated $4.61M sold.

Based on aggregated 13F filings for Q1 2023.